|
Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
NPH - 2025 Full Year Results
RAD - Radius Care Triples 1H26 NPAT
APL - Result for the six months ended 30 September 2025
November 19th Morning Report
Devon Funds Morning Note - 18 November 2025
Sanford delivers a record full year result
November 18th Morning Report
AIA - October Monthly Traffic Update
November 17th Morning Report
EROAD strengthening focus on ANZ opportunities